- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07951125
Tranexamic Acid for Recovery After Modified Radical Mastoidectomy in Patients With Chronic Suppurative Otitis Media
Clinical Study on the Application of Tranexamic Acid to Improve the Prognosis of Surgical Treatment for Chronic Suppurative Otitis Media
The main objective of this project is to conduct a multicentre, prospective, randomised, controlled clinical trial to evaluate the clinical value of tranexamic acid in patients undergoing mastoidectomy. The study population consists of patients with chronic suppurative otitis media scheduled to undergo mastoidectomy. They will be randomised in a 1:1 ratio to either the pre-operative intravenous tranexamic acid group or the saline control group; both groups will undergo treatment in accordance with standardised anaesthesia and surgical protocols. The main research components include:
- Evaluation of the dry ear rate: The primary outcome measure was to compare the difference in dry ear rates between the two groups one month post-operatively, in order to verify the effect of tranexamic acid on improving the dry ear rate following mastoidectomy. The assessment of the dry ear rate was carried out by an ENT specialist unaware of the study group allocation via clinical otoscopic examination; a dry ear was defined as the absence of discharge in the ear canal and complete epithelialisation of the mastoid surgical site. The assessment time point for the primary outcome measure was one month post-operatively.
- Postoperative hearing assessment: This will be assessed based on the improvement in hearing at 3 months postoperatively compared with preoperative levels.
- Safety assessment: The safety assessment will primarily include common adverse reactions associated with the use of tranexamic acid (e.g. nausea, vomiting, dizziness) and serious adverse events (e.g. venous thromboembolism, myocardial infarction, epileptic seizures). These will be comprehensively evaluated in conjunction with clinical signs and laboratory tests to ensure the safety and feasibility of the intervention.
Through this study, the project aims to determine whether tranexamic acid can effectively reduce the incidence of dry ear in the early postoperative period following mastoidectomy, and to provide evidence-based support for its clinical implementation.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: Haiyan An, MD,PhD
- Telefoonnummer: +86 135 2155 3036
- E-mail: anhaiyan76@163.com
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Peking University First Hospital
-
Contact:
- DongLiang Mu, MD,PhD
- Telefoonnummer: +86 17810370608
- E-mail: mudongliang@bjmu.edu.cn
-
Beijing, Beijing Municipality, China, 100044
- Peking University People's Hospital
-
Contact:
- Haiyan An, MD,PhD
- Telefoonnummer: +86 135 2155 3036
- E-mail: anhaiyan76@163.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18-65 years, regardless of sex
- American Society of Anesthesiologists (ASA) physical status I-II
- Patients diagnosed with chronic suppurative otitis media (CSOM) who have had an inadequate response to conservative medical treatment
- Patients scheduled to undergo microscopic open (canal wall-down) radical mastoidectomy
- Patients who provide written informed consent
Exclusion Criteria:
- Known allergy or hypersensitivity to tranexamic acid (TXA)
- Severe hepatic or renal disease (hepatic or renal decompensation); thromboembolic diseases, including deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction; a history of epilepsy, including seizures induced by any cause; or coagulation disorders (any of the following coagulation parameters-activated partial thromboplastin time [APTT], prothrombin time [PT], fibrinogen [FIB], or D-dimer [D-D]-exceeding 1.5 times the upper limit of the normal range)
- Use of anticoagulant or antiplatelet medications within 2 weeks before surgery, including aspirin, clopidogrel, warfarin, or other such medications
- Color blindness, pregnancy, or breastfeeding
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Normal Saline (NS) Group
An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision. |
An equivalent volume of normal saline will be administered intravenously 10 minutes before skin incision. |
|
Experimenteel: Tranexamic Acid (TXA) Group
Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision. |
Tranexamic acid 15 mg/kg will be administered intravenously 10 minutes before skin incision. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dry ear rate
Tijdsspanne: 1 month (±1 week) after surgery
|
A dry ear is defined as no exudate in the external auditory canal or mastoid cavity and complete epithelialization of the surgical cavity. Dry ear status will be assessed by an otolaryngologist using otoendoscopy. |
1 month (±1 week) after surgery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hearing improvement
Tijdsspanne: 3 months after surgery (±2 weeks)
|
Pure-tone audiometry will be used to assess hearing thresholds at 0.5, 1, 2, and 4 kHz. Air-conduction (AC), bone-conduction (BC), and air-bone gap (ABG) thresholds will be recorded at each frequency. |
3 months after surgery (±2 weeks)
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety and tolerability
Tijdsspanne: At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)
|
Adverse events will be assessed at postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks), including common adverse events such as nausea, vomiting, and dizziness, as well as serious adverse events such as arterial or venous thromboembolism, myocardial infarction, and seizures. These assessments will be used to evaluate the safety of preoperative intravenous administration of tranexamic acid in patients undergoing modified radical mastoidectomy. |
At postoperative day 1, 1 month (±1 week), and 3 months (±2 weeks)
|
Medewerkers en onderzoekers
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026PHB663-001
- 首发2026-2-4085 (Ander subsidie-/financieringsnummer: Beijing Municipal Health Commission)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data will not be shared with other researchers due to patient privacy and confidentiality considerations, as well as institutional data protection requirements. Only aggregated study results may be made publicly available through scientific publications.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .